Ellen VAN OBBERGHEN-SCHILLING
Adhesion Signaling and Stromal Reprogramming in the Tumor Microenvironment
- Understanding mechanisms regulating the expression and alternative splicing of oncofetal ECM proteins and how the presence of alternatively-spliced domains impacts their assembly and functions
- Elucidating how the tumor ECM enhances the invasive behavior of tumor cells, promotes the angiogenic phenotype of endothelial cells and blocks the anti-tumor functions of immune cells
- Obtaining clinically relevant knowledge about how the neoplastic ECM contributes to stromal immunosuppressive programs in human head and neck carcinomas
Our research focuses on the role of the extracellular matrix (ECM) in carcinoma progression, spread and response to therapy.
For a tumor to develop and expand, the growth-repressive environment of the host tissue must undergo significant changes. These changes, brought about through cancer cell-stromal interactions, include dramatic modifications in the molecular composition and architecture of the ECM. Re-expression of “oncofetal” matrix proteins, known to play determinant roles in tissue morphogenesis during embryonic development, participates in the pro-tumoral conversion of the stroma through complex signaling networks and biomechanical mechanisms that are not well understood. Our laboratory seeks to uncover mechanisms underlying tumor-induced stromagenic reprogramming and to elucidate how the neoplastic ECM enhances the invasive behavior of tumor cells, escape from immune surveillance systems and therapeutic resistance.
Efforts of the team are centered on head and neck squamous cell carcinoma (HNSCC), a tumor pathology for which we have established in vitro, ex vivo and in vivo experimental models through a collaborative network of basic and clinical research teams.
Our characterization of the ECM landscape of human HNSCC-associated fibroblasts allowed us to identify oncofetal fibronectin (FN) and 2 ECM receptors on carcinoma cells as key molecular determinants of the tumor-stroma dialog in HNSCC. Current projects aim: (i) to understand mechanisms regulating the expression of oncofetal ECM proteins and how the presence of alternatively spliced domains impacts the assembly/nanotopology and functions of the proteins, (ii) to elucidate how oncofetal components of the neoplastic ECM contribute to stromal immunosuppressive programs, and iii) to identify ECM-associated therapeutic targets and predictive biomarkers for improved efficacy of emerging treatments.
These aims are addressed through a complementary set of cellular, molecular and computational approaches involving the use of 3D culture models, full length recombinant matrix proteins and analysis of patient samples in collaboration with our clinical colleagues.
Understanding mechanisms regulating the expression and alternative splicing of oncofetal ECM proteins and how the presence of alternatively-spliced domains impacts their assembly and functions
Oncofetal FN differs from plasma FN by the presence of highly conserved “Extra Domains” that increase the repertoire of cellular receptors and alter the function of the protein in ways that we are investigating using an isoform-specific biological toolset and an interdisciplinary approach.
Elucidating how the neoplastic ECM contributes to the progression and spread of head and neck carcinomas
Using a variety of approaches including 3D culture systems and analysis of human tumors, and based on insights from a carcinogen-induced model of oral SCC in immune-competent mice (collaborators), we aim to understand how the neoplastic ECM promotes the invasive behavior of tumor cells and angiogenic phenotype of endothelial cells, and blocks tumor-suppressive functions of immune cells.
ECM reprogramming and anti-tumor immunity in human tumors
Immunomodulatory therapies are promising for HNSCC yet only a fraction patients respond. Thus offering better responses to these treatments is an urgent and unmet clinical need. To further understand ECM-regulated control of anti-tumor immunity in human tumors, and provide a foundation for clinically relevant discoveries, we are participating in biological studies linked to immunotherapy trials in different therapeutic settings.
CIAIS Delphine - +33 489150791
RUFF Michael - +33 489150791
Engineers & Technicians
- Efthymiou, G, Saint, A, Ruff, M, Rekad, Z, Ciais, D, Van Obberghen-Schilling, E et al.. Shaping Up the Tumor Microenvironment With Cellular Fibronectin. Front Oncol. 2020;10 :641. doi: 10.3389/fonc.2020.00641. PubMed PMID:32426283 PubMed Central PMC7203475.
- Hofman, P, Ayache, N, Barbry, P, Barlaud, M, Bel, A, Blancou, P et al.. The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. Cancers (Basel). 2019;11 (2):. doi: 10.3390/cancers11020250. PubMed PMID:30795607 PubMed Central PMC6406685.
- Soubies, E, Radwanska, A, Grall, D, Blanc-Féraud, L, Van Obberghen-Schilling, E, Schaub, S et al.. Nanometric axial resolution of fibronectin assembly units achieved with an efficient reconstruction approach for multi-angle-TIRF microscopy. Sci Rep. 2019;9 (1):1926. doi: 10.1038/s41598-018-36119-3. PubMed PMID:30760745 PubMed Central PMC6374485.
- Radwanska, A, Grall, D, Schaub, S, Divonne, SBF, Ciais, D, Rekima, S et al.. Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells. Sci Rep. 2017;7 (1):12762. doi: 10.1038/s41598-017-13008-9. PubMed PMID:28986537 PubMed Central PMC5630602.
- Degli Esposti, D, Sklias, A, Lima, SC, Beghelli-de la Forest Divonne, S, Cahais, V, Fernandez-Jimenez, N et al.. Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas. Genome Med. 2017;9 (1):33. doi: 10.1186/s13073-017-0419-z. PubMed PMID:28381277 PubMed Central PMC5382363.
- Gopal, S, Veracini, L, Grall, D, Butori, C, Schaub, S, Audebert, S et al.. Fibronectin-guided migration of carcinoma collectives. Nat Commun. 2017;8 :14105. doi: 10.1038/ncomms14105. PubMed PMID:28102238 PubMed Central PMC5253696.
- Rupp, T, Langlois, B, Koczorowska, MM, Radwanska, A, Sun, Z, Hussenet, T et al.. Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling. Cell Rep. 2016;17 (10):2607-2619. doi: 10.1016/j.celrep.2016.11.012. PubMed PMID:27926865 .
- Sakakini, N, Turchi, L, Bergon, A, Holota, H, Rekima, S, Lopez, F et al.. A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells. J. Biol. Chem. 2016;291 (20):10684-99. doi: 10.1074/jbc.M116.720698. PubMed PMID:27002148 PubMed Central PMC4865916.
- Thariat, J, Vignot, S, Lapierre, A, Falk, AT, Guigay, J, Van Obberghen-Schilling, E et al.. Integrating genomics in head and neck cancer treatment: Promises and pitfalls. Crit. Rev. Oncol. Hematol. 2015;95 (3):397-406. doi: 10.1016/j.critrevonc.2015.03.005. PubMed PMID:25979769 .
- Veracini, L, Grall, D, Schaub, S, Beghelli-de la Forest Divonne, S, Etienne-Grimaldi, MC, Milano, G et al.. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2015;6 (10):7570-83. doi: 10.18632/oncotarget.3071. PubMed PMID:25779657 PubMed Central PMC4480700.
- Turchi, L, Debruyne, DN, Almairac, F, Virolle, V, Fareh, M, Neirijnck, Y et al.. Tumorigenic potential of miR-18A* in glioma initiating cells requires NOTCH-1 signaling. Stem Cells. 2013;31 (7):1252-65. doi: 10.1002/stem.1373. PubMed PMID:23533157 .
- Thariat, J, Bensadoun, RJ, Etienne-Grimaldi, MC, Grall, D, Penault-Llorca, F, Dassonville, O et al.. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin. Cancer Res. 2012;18 (18):5123-33. doi: 10.1158/1078-0432.CCR-12-1518. PubMed PMID:22855581 .
- Thariat, J, Etienne-Grimaldi, MC, Grall, D, Bensadoun, RJ, Cayre, A, Penault-Llorca, F et al.. Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin. Cancer Res. 2012;18 (5):1313-22. doi: 10.1158/1078-0432.CCR-11-2339. PubMed PMID:22228639 .
- Van Obberghen-Schilling, E, Tucker, RP, Saupe, F, Gasser, I, Cseh, B, Orend, G et al.. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int. J. Dev. Biol. 2011;55 (4-5):511-25. doi: 10.1387/ijdb.103243eo. PubMed PMID:21769776 .
- Cagnol, S, Mansour, A, Van Obberghen-Schilling, E, Chambard, JC. Raf-1 activation prevents caspase 9 processing downstream of apoptosome formation. J Signal Transduct. 2011;2011 :834948. doi: 10.1155/2011/834948. PubMed PMID:21637382 PubMed Central PMC3100593.
- Cseh, B, Fernandez-Sauze, S, Grall, D, Schaub, S, Doma, E, Van Obberghen-Schilling, E et al.. Autocrine fibronectin directs matrix assembly and crosstalk between cell-matrix and cell-cell adhesion in vascular endothelial cells. J. Cell. Sci. 2010;123 (Pt 22):3989-99. doi: 10.1242/jcs.073346. PubMed PMID:20980391 .
- Stanchi, F, Grashoff, C, Nguemeni Yonga, CF, Grall, D, Fässler, R, Van Obberghen-Schilling, E et al.. Molecular dissection of the ILK-PINCH-parvin triad reveals a fundamental role for the ILK kinase domain in the late stages of focal-adhesion maturation. J. Cell. Sci. 2009;122 (Pt 11):1800-11. doi: 10.1242/jcs.044602. PubMed PMID:19435803 .
- Fernandez-Sauze, S, Grall, D, Cseh, B, Van Obberghen-Schilling, E. Regulation of fibronectin matrix assembly and capillary morphogenesis in endothelial cells by Rho family GTPases. Exp. Cell Res. 2009;315 (12):2092-104. doi: 10.1016/j.yexcr.2009.03.017. PubMed PMID:19332054 .
- Fantozzi, I, Grall, D, Cagnol, S, Stanchi, F, Sudaka, A, Brunstein, MC et al.. Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol. 2008;47 (8):1502-12. doi: 10.1080/02841860802089801. PubMed PMID:18607838 .
- Rosso, L, Pierson, PM, Golfier, C, Peteri-Brunbäck, B, Deroanne, C, Van Obberghen-Schilling, E et al.. Pituicyte stellation is prevented by RhoA-or Cdc42-dependent actin polymerization. Cell. Mol. Neurobiol. 2007;27 (6):791-804. doi: 10.1007/s10571-007-9176-7. PubMed PMID:17712627 .
2 Postdoctoral Research Positions
in Nice France
To study the impact of the tumor matrix environment on immune cells
Applications are invited for 2 full-time postdoctoral positions in tumor/immuno-biology to study the implication of extracellular matrix (ECM) components in the immunosuppressive reprogramming of the tumor microenvironment in head and neck cancer associated with tobacco use. The project aims to provide a better understanding of the cellular, molecular and functional interactions between tumor-associated innate immune cells and ECM molecules during cancerogenesis of head and neck squamous epithelium. Studies will be conducted using an immunocompetent mouse model of tongue carcinogenesis and ex vivo 3D reconstituted ECM systems. Implications of our findings for human cancer and therapeutic intervention will be determined by analyzing samples from human patients. This collaborative project between teams in Nice and Strasbourg will provide training in an interdisciplinary context at the crossroads of immunology, cell and molecular biology and human tumor pathology.
One position is available in the Institute of Biology Valrose (iBV) (http://ibv.unice.fr) and one position in the Institute of Molecular and Cellular Pharmacology (IPMC) (https://www.ipmc.cnrs.fr/cgi-bin/ipmcx.cgi). These leading Research Centers of the Université Côte d’Azur are equipped with state of the art core facilities and dynamic scientific environments in which English is the working language. The iBV team headed by E. Van Obberghen-Schilling has an expertise cell-matrix adhesion and matrix-driven signaling in squamous cell carcinomas of the head and neck. F. Anjuère, leader of the IPMC team “Immune regulations at muco-cutaneous surfaces” with V. Braud, is an expert in mucosal immunology and has led numerous studies aimed at developing mucosal vaccines against infectious diseases and cancer. Clinical collaborators at the head and neck oncology team of the Centre Antoine Lacassagne (CAL) and University Head and Neck Institute (IUFC) are actively involved in clinical studies focused on immunotherapy.
The successful post-doctoral candidates should have a strong background in cell biology/immunology and experience in cellular/tissue imaging. Excellent written and spoken English communication skills, strong self-motivation, the ability to work both independently and collaboratively is expected.
Please send applications (full CV including research interests and the name of 2-3 referees in a single pdf document) and requests for further information by email to:
Ellen Van Obberghen-Schilling (email@example.com) – Fabienne Anjuère (firstname.lastname@example.org)
Starting date: November 2017
2001 - Research Award in Physiology/Pathology, Inserm
1996 - Young Scientist Award, FRM
1991 - Prix Exceptionnel, Groupe d'Etudes sur l'Hémostase et la Thrombose
iBV - Institut de Biologie Valrose
Université Nice Sophia Antipolis
Faculté des Sciences
06108 Nice cedex 2